share_log

Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3

Moomoo 24/7 ·  Mar 27 10:05

Cantor Fitzgerald analyst Ross Osborn maintains Lucid Diagnostics (NASDAQ:LUCD) with a Overweight and lowers the price target from $3.8 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment